Navigation Links
New Research Provides Insight Into How Doctors View Effectiveness, Quality and Safety of Generic Medications
Date:1/11/2011

WOONSOCKET, R.I., Jan. 11, 2011 /PRNewswire/ -- A new study by researchers at Harvard, Brigham and Women's Hospital and CVS Caremark finds that 23 percent of doctors' have negative perceptions of the effectiveness and quality of generic drugs and that may lead to doctors prescribing unnecessarily expensive medications. In a study published in the Annals of Pharmacotherapy, the researchers said, "Overall, we found that the majority of physicians are comfortable with the efficacy of generic medications and are comfortable using generics themselves. However, there is a meaningful proportion who express concerns about generics . . . These beliefs could represent an important barrier to greater generic use and could contribute to elevated prescription costs for patients, insurance providers and society."

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

Lead author of the study William Shrank, MD, MSHS, of Brigham and Women's Hospital and Harvard said, "While there are many studies about how consumers and patients view generics, we thought it would be important to also look at the perception of generics by prescribers, because understanding the physician's perception can help us determine if there are other potential barriers to the greater use of generics. We don't have clear insight as to what might influence a prescriber's behavior, and as we look to develop programs to encourage more cost-effective pharmacy care, this is an area industry and policy makers should be reviewing. We know that if we help patients access less expensive medications, they are more likely to take them."  

The researchers surveyed more than 2,700 physicians and received 506 responses from prescribers representing both specialists and general practitioners. More than 60 percent of the physicians surveyed were between 35 and 54 with physicians over 55 representing about 30 percent of the survey group; physicians aged 25 to 34 made up 9 per
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
2. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
4. ReSearch Pharmaceutical Services to be Acquired by Warburg Pincus
5. Topical China Industries Research Reports Published at MarketPublishers.com
6. Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan
7. Research from Best Practices, LLC Delivers Effective Market Education Tactics and Strategies for New Oncology Products
8. An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
9. Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
10. Christopher Codeanne Appointed Chief Financial Officer of Premier Research Group
11. New Topical Research Reports by iData Research Published by MarketPublishers.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and ... for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D ... pre-procedural, high-precision positioning to treat aortic stenosis ailments.  ... available as part of Philips IntelliSpace Portal ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
(Date:8/21/2014)... News) -- In a new review of seafood safety, ... tuna due to concerns about mercury exposure. "We,re ... to shrimp as the most commonly eaten seafood in ... all tuna," Jean Halloran, director of food policy initiatives ... said in a news release from the group. ...
(Date:8/21/2014)... (HealthDay News) -- Using two types of polio vaccines ... may boost efforts to eradicate polio, a new study ... India found that giving the Salk inactivated poliovirus vaccine ... Sabin live-attenuated oral poliovirus vaccine (OPV) appeared to improve ... The findings, reported in the Aug. 22 issue of ...
(Date:8/21/2014)... 2014 The Onder Law Firm, nationally-renowned ... law, announces the launch of a new Morcellator Cancer ... morcellator surgery lawsuits for cancer claims, including ... warning and the July 2014 morcellator recall. , ... 2014 FDA warning on morcellator surgery and cancer, federal ...
(Date:8/21/2014)... 2014. Researchers have published a study examining racial ... with motor complete spinal cord injury (SCI). The ... discharge and follow-up among patients with motor complete ... August 2 by the Archives of Physical ... small but significant differences in self-care and mobility ...
Breaking Medicine News(10 mins):Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... Organizations, Advocates, Government Agencies, and Scientists from Academic Institutions ... ... 13 Leadership and senior staff of,twenty- seven breast ... along with experts from government agencies, scientists,from academic institutions ...
... Society of America (GSA) has chosen W. Andrew Achenbaum ... of the Donald P. Kent Award. This distinguished honor ... exemplifies the highest standards for professional leadership in gerontology ... larger society. , The award presentation will take ...
... has chosen Nancy L. Pedersen of Sweden,s Karolinska Institutet ... Contribution to Gerontology. This prize is given annually to ... a new synthesis and perspective or have yielded original ... the literature. , The award presentation will take place ...
... operated on, or the wrong transplant, study found , , TUESDAY, ... in eye surgery, say U.S. researchers who analyzed 106 cases ... the wrong site or using wrong procedure. , The ... College in New York found: , The most common ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
... - Seattle & King County and RediClinic, offers Seattle-area residents a, convenient opportunity to get ... themselves and the many lives they touch, - Vaccination ... ... between mid ...
Cached Medicine News:Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4Health News:Eye Surgery Errors Rare But Serious 2Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: